Finasteride Counseling for Male Androgenetic Alopecia Should Reflect Updated Findings on Prostate Cancer Risk

Affiliations

¹ The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York, USA.
² Pilaris Dermatology, New York, New York, USA.

Christine C Akoh et al. Skin Appendage Disord. 2020 Mar.

. 2020 Mar;6(2):130-131.

doi: 10.1159/000504893. Epub 2020 Jan 7.

¹ The Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, New York, USA.
² Pilaris Dermatology, New York, New York, USA.

No abstract available

Conflict of interest statement

C.C.A. declares no conflicts of interest. K.S. has ownership interest in Pilaris Inc.

1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul;349((3)):215–24. - PubMed
1. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006 Aug;98((16)):1128–33. - PubMed
1. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007 May;177((5)):1749–52. - PubMed
1. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep;99((18)):1375–83. - PubMed
1. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008 Aug;1((3)):174–81. - PMC - PubMed